{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:29:12Z","timestamp":1787030952072,"version":"build-2736575974"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Med Health Sci Res"],"published-print":{"date-parts":[[2016]]},"DOI":"10.4103\/2141-9248.183943","type":"journal-article","created":{"date-parts":[[2016,6,13]],"date-time":"2016-06-13T01:23:40Z","timestamp":1465781020000},"page":"139","source":"Crossref","is-referenced-by-count":20,"title":["The wonders of phosphodiesterase-5 inhibitors: A majestic history"],"prefix":"10.4103","volume":"6","author":[{"given":"AS","family":"Elhwuegi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2141-9248.183943-1","first-page":"557","volume-title":"Role of endothelium in responses of vascular smooth muscle","author":"Furchgott","year":"1983","journal-title":"Circ Res"},{"key":"key-10.4103\/2141-9248.183943-2","first-page":"277","volume-title":"Nitroglycerin and Nitric Oxide \u2013 A rondo of themes in cardiovascular therapeutics","author":"Steinhorn","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2141-9248.183943-3","first-page":"1288","volume-title":"Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: Benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments","author":"Keravis","year":"2012","journal-title":"Br J Pharmacol"},{"key":"key-10.4103\/2141-9248.183943-4","first-page":"829","volume-title":"Nitric oxide synthases: Regulation and function","author":"F\u00f6rstermann","year":"2012","journal-title":"Eur Heart J"},{"key":"key-10.4103\/2141-9248.183943-5","first-page":"525","volume-title":"cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action","author":"Francis","year":"2010","journal-title":"Pharmacol Rev"},{"key":"key-10.4103\/2141-9248.183943-6","first-page":"1288","volume-title":"Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: Benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments","author":"Keravis","year":"2012","journal-title":"Br J Pharmacol"},{"key":"key-10.4103\/2141-9248.183943-7","first-page":"247","volume-title":"Cyclic nucleotide-dependent relaxation pathways in vascular smooth muscle","author":"Morgado","year":"2012","journal-title":"Cell Mol Life Sci"},{"key":"key-10.4103\/2141-9248.183943-8","first-page":"170","volume-title":"Contribution of endothelial nitric oxide to blood pressure in humans","author":"Gamboa","year":"2007","journal-title":"Hypertension"},{"key":"key-10.4103\/2141-9248.183943-9","first-page":"239","volume-title":"Hypertension in mice lacking the gene for endothelial nitric oxide synthase","author":"Huang","year":"1995","journal-title":"Nature"},{"key":"key-10.4103\/2141-9248.183943-10","first-page":"1428","volume-title":"Endothelial cell-specific liver kinase B1 deletion causes endothelial dysfunction and hypertension in mice in vivo","author":"Zhang","year":"2014","journal-title":"Circulation"},{"key":"key-10.4103\/2141-9248.183943-11","first-page":"262","volume-title":"Modulation of soluble guanylate cyclase for the treatment of erectile dysfunction","author":"Lasker","year":"2013","journal-title":"Physiology (Bethesda)"},{"key":"key-10.4103\/2141-9248.183943-12","first-page":"341","volume-title":"Sub-cellular targeting of constitutive NOS in health and disease","author":"Zhang","year":"2012","journal-title":"J Mol Cell Cardiol"},{"key":"key-10.4103\/2141-9248.183943-13","first-page":"80","volume-title":"Nitric oxide synthase regulation of cardiac excitation-contraction coupling in health and disease","author":"Simon","year":"2014","journal-title":"J Mol Cell Cardiol"},{"key":"key-10.4103\/2141-9248.183943-14","first-page":"388","volume-title":"Nitric oxide and cardiac function: Ten years after, and continuing","author":"Massion","year":"2003","journal-title":"Circ Res"},{"key":"key-10.4103\/2141-9248.183943-15","first-page":"1474","volume-title":"Oxidative stress regulates left ventricular PDE5 expression in the failing heart","author":"Lu","year":"2010","journal-title":"Circulation"},{"key":"key-10.4103\/2141-9248.183943-16","first-page":"2231","volume-title":"Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes","author":"Zhang","year":"2008","journal-title":"Cell Signal"},{"key":"key-10.4103\/2141-9248.183943-17","first-page":"408","volume-title":"Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice","author":"Pokreisz","year":"2009","journal-title":"Circulation"},{"key":"key-10.4103\/2141-9248.183943-18","first-page":"5193","volume-title":"An L-arginine\/nitric oxide pathway present in human platelets regulates aggregation","author":"Radomski","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.4103\/2141-9248.183943-19","first-page":"167","volume-title":"Novel roles of cAMP\/cGMP-dependent signaling in platelets","author":"Smolenski","year":"2012","journal-title":"J Thromb Haemost"},{"key":"key-10.4103\/2141-9248.183943-20","first-page":"154","volume-title":"Antiplatelet therapies for the treatment of cardiovascular disease","author":"Michelson","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"key-10.4103\/2141-9248.183943-21","first-page":"78","volume-title":"Inhibition of exercise-induced asthma by an orally absorbed mast cell stabilizer (M and B 22,948)","author":"Rudd","year":"1983","journal-title":"Br J Dis Chest"},{"key":"key-10.4103\/2141-9248.183943-22","first-page":"S252","volume-title":"Phosphodiesterase inhibitors","author":"Boswell-Smith","year":"2006","journal-title":"Br J Pharmacol"},{"key":"key-10.4103\/2141-9248.183943-23","first-page":"843","volume-title":"Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle","author":"Ignarro","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"key-10.4103\/2141-9248.183943-24","first-page":"90","volume-title":"Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission","author":"Rajfer","year":"1992","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2141-9248.183943-25","first-page":"1208","volume-title":"Erectile hydraulics: Maximizing inflow while minimizing outflow","author":"Meldrum","year":"2014","journal-title":"J Sex Med"},{"key":"key-10.4103\/2141-9248.183943-26","first-page":"3418","volume-title":"Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: The proper drug for the proper patient","author":"Corona","year":"2011","journal-title":"J Sex Med"},{"key":"key-10.4103\/2141-9248.183943-27","first-page":"902","volume-title":"Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: A systematic review and network meta-analysis","author":"Yuan","year":"2013","journal-title":"Eur Urol"},{"key":"key-10.4103\/2141-9248.183943-28","first-page":"970","volume-title":"Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors.Review of the literature","author":"Lombardi","year":"2012","journal-title":"J Sex Med"},{"key":"key-10.4103\/2141-9248.183943-29","first-page":"53","volume-title":"The role of nitric oxide in erectile dysfunction: Implications for medical therapy","author":"Burnett","year":"2006","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"key-10.4103\/2141-9248.183943-30","first-page":"1333","volume-title":"An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors","author":"Bruzziches","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"key-10.4103\/2141-9248.183943-31","first-page":"766","volume-title":"The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease","author":"Nehra","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"key-10.4103\/2141-9248.183943-32","first-page":"820","volume-title":"The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype","author":"Shon","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"key-10.4103\/2141-9248.183943-33","first-page":"e9052","volume-title":"Food and drug administration cardiovascular and renal drugs advisory committee.Proceedings of the 99th meeting of the food and drug administration cardiovascular and renal drugs advisory committee; May 29th and 30th, 2003","author":"Borer","year":"2003","journal-title":"Circulation"},{"key":"key-10.4103\/2141-9248.183943-34","first-page":"13","volume-title":"Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function","author":"Miner","year":"2006","journal-title":"Clin Ther"},{"key":"key-10.4103\/2141-9248.183943-35","first-page":"111","volume-title":"Emerging drug therapies for benign prostatic hyperplasia","author":"Bullock","year":"2006","journal-title":"Expert Opin Emerg Drugs"},{"key":"key-10.4103\/2141-9248.183943-36","first-page":"809","volume-title":"Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia","author":"Gacci","year":"2011","journal-title":"Eur Urol"},{"key":"key-10.4103\/2141-9248.183943-37","first-page":"94","volume-title":"Tadalafil \u2013 A therapeutic option in the management of BPH-LUTS","author":"Carson","year":"2014","journal-title":"Int J Clin Pract"},{"key":"key-10.4103\/2141-9248.183943-38","first-page":"405","volume-title":"Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: Integrated data analyses from 4 placebo controlled clinical studies","author":"Brock","year":"2014","journal-title":"J Urol"},{"key":"key-10.4103\/2141-9248.183943-39","first-page":"1539","volume-title":"The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: A systematic review and meta-analysis","author":"Yan","year":"2014","journal-title":"J Sex Med"},{"key":"key-10.4103\/2141-9248.183943-40","first-page":"727","volume-title":"Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia","author":"Casab\u00e9","year":"2014","journal-title":"J Urol"},{"key":"key-10.4103\/2141-9248.183943-41","first-page":"1883","volume-title":"Right ventricular function and failure: Report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure","author":"Voelkel","year":"2006","journal-title":"Circulation"},{"key":"key-10.4103\/2141-9248.183943-42","first-page":"2250","volume-title":"ACCF\/AHA 2009 expert consensus document on pulmonary hypertension: A report of the American College of Cardiology Foundation task force on expert consensus documents and the American heart association: Developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the pulmonary hypertension association","author":"McLaughlin","year":"2009","journal-title":"Circulation"},{"key":"key-10.4103\/2141-9248.183943-43","first-page":"2894","volume-title":"Pulmonary arterial hypertension and response to tadalafil (PHIRST) study group.Tadalafil therapy for pulmonary arterial hypertension","author":"Gali\u00e8","year":"2009","journal-title":"Circulation"},{"key":"key-10.4103\/2141-9248.183943-44","first-page":"224","volume-title":"Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre","author":"Douwes","year":"2014","journal-title":"Heart"},{"key":"key-10.4103\/2141-9248.183943-45","first-page":"12","volume-title":"Pharmacotherapy in pulmonary arterial hypertension: A systematic review and meta-analysis","author":"Ryerson","year":"2010","journal-title":"Respir Res"}],"container-title":["Annals of Medical and Health Sciences Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2016,6,13]],"date-time":"2016-06-13T01:23:40Z","timestamp":1465781020000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.amhsr.org\/text.asp?2016\/6\/3\/139\/183943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"alternative-id":["183943"],"URL":"https:\/\/doi.org\/10.4103\/2141-9248.183943","relation":{},"ISSN":["2141-9248"],"issn-type":[{"value":"2141-9248","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}